Cidara Therapeutics(CDTX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 • Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeutic • Enrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the Northern Hemisphere by December 2025; Phase 3 initiation triggered $45.0 million milestone payment to Janssen • BARDA award to support expanded manufacturing and clinical development of CD388 • FDA granted Breakthrough Therapy designation to CD388 • Conference call and webcast ...